Headlands Technologies LLC Sells 2,903 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Headlands Technologies LLC reduced its investment in TransMedics Group, Inc. by 25.8% during the first quarter, maintaining a holding of 8,357 shares worth approximately $562,000.
• TransMedics Group reported a strong quarterly earnings result, with earnings per share of $0.92, significantly exceeding analyst expectations of $0.48 and a year-over-year revenue increase of 37.7%.
• Recent analyst ratings for TransMedics Group show a mix of recommendations, including upgrades from firms like Canaccord Genuity and Oppenheimer, with an average target price of $123.00.

Headlands Technologies LLC lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 25.8% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 8,357 shares of the company's stock after selling 2,903 shares during the period. Headlands Technologies LLC's holdings in TransMedics Group were worth $562,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. NBC Securities Inc. acquired a new position in TransMedics Group during the 1st quarter valued at about $25,000. Hager Investment Management Services LLC boosted its stake in TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. CWM LLC lifted its position in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after buying an additional 155 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of TransMedics Group by 551.7% in the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after buying an additional 1,324 shares during the last quarter. Finally, Sava Infond d.o.o. boosted its stake in shares of TransMedics Group by 46.7% in the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock worth $148,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TMDX. Morgan Stanley boosted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Canaccord Genuity Group boosted their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Finally, Oppenheimer boosted their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director owned 12,134 shares in the company, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,418 shares of company stock worth $818,833 over the last 90 days. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Stock Performance

TransMedics Group stock traded up $12.76 during trading on Monday, hitting $127.26. The stock had a trading volume of 2,080,043 shares, compared to its average volume of 1,359,905. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The stock's 50 day moving average is $123.91 and its two-hundred day moving average is $98.12. The stock has a market cap of $4.34 billion, a price-to-earnings ratio of 65.94 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. The business's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.35 earnings per share. As a group, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.